Publications

• A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV
  SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., Alves, J., … Pingoud, A. (1992). A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV. BIOCHEMISTRY, 31(20), 4808–4815.
• Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
  Liedtke, M., Hamlin, P. A., Moskowitz, C. H., & Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. ANNALS OF ONCOLOGY, 17(6), 909–913.
• Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
  Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581–85.
• Therapeutic targeting of MLL Liedtke, M., & Cleary, M. L. (2009). Therapeutic targeting of MLL. BLOOD, 113(24), 6061–6068.
  
• Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6 Liedtke, M., Ayton, P. M., Somervaille, T. C. P., Smith, K. S., & Cleary, M. L. (2010). Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. BLOOD, 116(1), 63–70.
  
• 
  
• 
  
• 
  
• 
  
• 
  
• The Transcription Factor Encyclopedia Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., Cheung, W. A., … Wasserman, W. W. (2012). The Transcription Factor Encyclopedia. GENOME BIOLOGY, 13(3).
  
• 
  
• 
  
• Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Hematology (Amsterdam, Netherlands).
  
• 
  
• Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Kumar, R. (2013). Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 11–17.
  
• A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leukemia & Lymphoma, 54(10), 2231–2235.
  
• 
  
• 
  
• 
  
• Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. ONCOGENE, 17(15), 1889–1892.
  
• 
  
• Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., … Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357–1358.
  
• A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML) Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347–47.
  
• Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2011). Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy. JOURNAL OF CARDIAC FAILURE, 17(8), S45–S46.
  
• 
  
• Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., Natkunam, Y., & Warnke, R. A. (2014). Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. American Journal of Surgical Pathology, 38(9), 1298–1304.
  
• Effects of serum and plasma matrices on multiplex immunoassays. Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., & Maecker, H. T. (2014). Effects of serum and plasma matrices on multiplex immunoassays. Immunologic Research, 58(2-3), 224–33.
  
• Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia Dinner, S., Lee, D., & Liedtke, M. (2014). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(8), 1715–24.
  
• 
  
• 
  
• 
  
• Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma Hansmann, L., Blum, L., Ju, C.-H., Liedtke, M., Robinson, W. H., & Davis, M. M. (2015). Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma. CANCER IMMUNOLOGY RESEARCH, 3(6), 650–60.
  
• CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Iwasaki, M., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015). CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell Stem Cell, 17(4), 412–21.
  
• Multiple Myeloma, Version 2.2016 Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2015). Multiple Myeloma, Version 2.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1398–1435.
  
• A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59.
  
• NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2016). NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Journal of the National Comprehensive Cancer Network , 14(4), 389–400.
  
• First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., Zonder, J., … Liedtke, M. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology , 34(10), 1097–1103.
  
• 
  
• 
  
• Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., … Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740–53.
  
• Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2016). Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(4), 389–400.
  
• Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., … Kumar, R. (2017). Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(2), 230-?
  
• 
  
• 
  
• Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2018). Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia Research, 67, 17–20.
  
• Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).
  
• NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY Liedtke, M., Comenzo, R., Landau, H., Sanchorawala, V., Weiss, B., Zonder, J., … Gertz, M. (2017). NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(11), 825.
  
• NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response Liedtke, M. M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response. EUROPEAN JOURNAL OF HEART FAILURE, 19, 441.
  
• A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis Cohen, A. D., Scott, E. C., Liedtke, M., Kaufman, J. L., Landau, H., Vesole, D. H., … Durie, B. G. M. (2014). A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. BLOOD, 124(21).
  
• FIRST-IN-HUMAN MULTICENTER STUDY OF BB2121 ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS Lin, Y., Berdeja, J., Raje, N., Munshi, N., Siegel, D., Liedtke, M., … Kochenderfer, J. (2017). FIRST-IN-HUMAN MULTICENTER STUDY OF BB2121 ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS. HAEMATOLOGICA, 102, 21.
  
• 
  
• Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study Pollyea, D. A., Kohrt, H. E., Gallegos, L., Zhang, B., Figueroa, M., Melnick, A., … Medeiros, B. C. (2011). Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
  
• PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN Jabbour, E., Advani, A., Stelljes, M., Stock, W., Liedtke, M., Goekbuget, N., … Kantarjian, H. M. (2017). PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN. HAEMATOLOGICA, 102, 198.
  
• NEOD001 DEMONSTRATES RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT RENAL DYSFUNCTION Liedtke, M., Comenzo, R. L., Landau, H., Seldin, D., Weiss, B., Zonder, J., … Gertz, M. A. (2016). NEOD001 DEMONSTRATES RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT RENAL DYSFUNCTION. NEPHROLOGY DIALYSIS TRANSPLANTATION, 31, 103.
  
• Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2015). Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. BLOOD, 126(23).
  
• Long-Term Outcomes in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin: Results from the Phase 3 INOVATE Study Ali, S., Stelljes, M., DeAngelo, D. J., Liedtke, M., Stock, W., Gokbuget, N., … Kantarjian, H. M. (2018). Long-Term Outcomes in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin: Results from the Phase 3 INOVATE Study. BRITISH JOURNAL OF HAEMATOLOGY, 181, 38.
  
• The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. Liedtke, M., Merlini, G., Landau, H. J., Comenzo, R., Seldin, D. C., Weiss, B. M., … Gertz, M. A. (2015). The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• ORAL INVESTIGATIONAL PROTEASOME INHIBITOR IXAZOMIB CITRATE (MLN9708) PLUS LENALIDOMIDE-DEXAMETHASONE IN ELDERLY PATIENTS (PTS) WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA Richardson, P. G., Rosenbaum, C. A., Hofmeister, C. C., Htut, M., Vesole, D. H., Berdeja, J. G., … Baz, R. (2014). ORAL INVESTIGATIONAL PROTEASOME INHIBITOR IXAZOMIB CITRATE (MLN9708) PLUS LENALIDOMIDE-DEXAMETHASONE IN ELDERLY PATIENTS (PTS) WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA. HAEMATOLOGICA, 99, 106.
  
• NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2016). NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study. EUROPEAN HEART JOURNAL, 37, 220.
  
• Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of US Intergroup Trial C10403 Stock, W., Luger, S. M., Advani, A. S., Geyer, S., Harvey, R. C., Mullighan, C. G., … Larson, R. A. (2014). Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of US Intergroup Trial C10403. BLOOD, 124(21).
  
• AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions. Witteles, W., Witteles, R., Liedtke, M., Arai, S., Lafayette, R., George, T. I., & Schrier, S. L. (2010). AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions. BLOOD, 116(21), 1649.
  
• 
  
• EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN (INO) VS STANDARD OF CARE (SOC) IN SALVAGE 1 OR 2 PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): AN ONGOING GLOBAL PHASE 3 STUDY DeAngelo, D. J., Stelljes, M., Martinelli, G., Kantarjian, H., Liedtke, M., Stock, W., … Advani, A. S. (2015). EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN (INO) VS STANDARD OF CARE (SOC) IN SALVAGE 1 OR 2 PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): AN ONGOING GLOBAL PHASE 3 STUDY. HAEMATOLOGICA, 100, 337.
  
• Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. Gertz, M. A., Landau, H. J., Comenzo, R., Seldin, D. C., Weiss, B. M., Zonder, J. A., … Liedtke, M. (2015). Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients Pollyea, D. A., Kohrt, H. E., Rajwanshi, R., Gallegos, L., Berube, C., Coutre, S. E., … Medeiros, B. C. (2010). An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
  
• NEOD001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With AL Amyloidosis and Persistent Organ Dysfunction Liedtke, M., Landau, H., Comenzo, R., Seldin, D., Weiss, B., Zonder, J., … Gertz, M. A. (2015). NEOD001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With AL Amyloidosis and Persistent Organ Dysfunction. JOURNAL OF CARDIAC FAILURE, 21(8), S15.
  
• NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., … Shead, D. A. (2018). NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(1), 11–20.
  
• Clinical implications of gastrointestinal symptoms in systemic amyloidosis Yen, T., Chen, F. W., Witteles, R. M., Liedtke, M., & Nguyen, L. A. (2018). Clinical implications of gastrointestinal symptoms in systemic amyloidosis. NEUROGASTROENTEROLOGY AND MOTILITY, 30(4), e13229.
  
• NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response. ONCOLOGY RESEARCH AND TREATMENT, 40, 34–35.
  
• NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY Gertz, M., Comenzo, R. L., Landau, H., Sanchorawala, Weiss, B. M., Zonder, J. A., … Liedtke, M. (2017). NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 22(3), 289–90.
  
• PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS TREATED WITH NEOD001 ACHIEVE RAPID ORGAN RESPONSES THAT ARE INDEPENDENT OF PREVIOUS PLASMA CELL-DIRECTED THERAPIES Gertz, M. A., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Liedtke, M. (2017). PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS TREATED WITH NEOD001 ACHIEVE RAPID ORGAN RESPONSES THAT ARE INDEPENDENT OF PREVIOUS PLASMA CELL-DIRECTED THERAPIES. HAEMATOLOGICA, 102, 3.
  
• 
  
• Novel therapeutic approaches for AL amyloid Liedtke, M. (2017). Novel therapeutic approaches for AL amyloid. ONCOLOGY RESEARCH AND TREATMENT, 40, 194.
  
• Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., … Advani, A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. BLOOD ADVANCES, 1(15), 1167–80.
  
• Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy Pollyea, D. A., Zehnder, J. L., Coutre, S., Gotlib, J., Gallegos, L., Greenberg, P., … Medeiros, B. C. (2012). Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. BLOOD, 120(21).
  
• INOTUZUMAB OZOGAMICIN FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL: EFFICACY AND SAFETY BY PRIOR THERAPY DeAngelo, D. J., Jabbour, E. J., Stelljes, M., Liedtke, M., Stock, W., Goekbuget, N., … Kantarjian, H. M. (2016). INOTUZUMAB OZOGAMICIN FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL: EFFICACY AND SAFETY BY PRIOR THERAPY. HAEMATOLOGICA, 101, 184.
  
• NEOD001 DEMONSTRATES CARDIAC AND RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH AMYLOID LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION Liedtke, M., Comenzo, R., Landau, H., Seldin, D., Weiss, B., Zonder, J., … Gertz, M. A. (2016). NEOD001 DEMONSTRATES CARDIAC AND RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH AMYLOID LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 67(13), 1301.
  
• Inotuzumab ozogamicin (InO) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) in the global phase 3 randomized controlled ino-vate trial: efficacy and safety by age and prior therapy Stelljes, M., Kreuzer, K.-A., Deangelo, D. J., Advani, A. S., Goekbuget, N., Liedtke, M., … Kantarjian, H. M. (2016). Inotuzumab ozogamicin (InO) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) in the global phase 3 randomized controlled ino-vate trial: efficacy and safety by age and prior therapy. ONCOLOGY RESEARCH AND TREATMENT, 39, 201–2.
  
• EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN OLDER PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ENROLLED IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL Jabbour, E. J., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Goekbuget, N., … Kantarjian, H. M. (2016). EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN OLDER PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA ENROLLED IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL. HAEMATOLOGICA, 101, 32.
  
• NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction Independently of Previous Hematological Response Gertz, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Liedtke, M. (2018). NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction Independently of Previous Hematological Response. ONCOLOGY RESEARCH AND TREATMENT, 41, 19.
  
• TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION Richardson, P., Hofmeister, C., Rosenbaum, C., Htut, M., Vesole, D., Berdeja, J., … Baz, R. (2017). TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION. HAEMATOLOGICA, 102, 317–18.
  
• OOVERALL SURVIVAL IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS RECEIVING INOTUZUMAB OZOGAMICIN VS STANDARD CARE IN THE PHASE 3 INO-VATE STUDY Kantarjian, H. M., DeAngelo, D. J., Advani, A. S., Liedtke, M., Stock, W., Goekbuget, N., … Stelljes, M. (2016). OOVERALL SURVIVAL IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS RECEIVING INOTUZUMAB OZOGAMICIN VS STANDARD CARE IN THE PHASE 3 INO-VATE STUDY. HAEMATOLOGICA, 101, 339.
  
• 
  
• NEOD001 Demonstrates Cardiac Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction in a Phase 1/2 Study Expansion Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B., Zonder, J., … Gertz, M. A. (2016). NEOD001 Demonstrates Cardiac Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction in a Phase 1/2 Study Expansion. JOURNAL OF CARDIAC FAILURE, 22(8), S64.
  
• NEOD001 DEMONSTRATES CARDIAC AND RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH AL AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION Liedtke, M., Landau, H., Comenzo, R., Seldin, D., Weiss, B., Zonder, J., … Gertz, M. A. (2015). NEOD001 DEMONSTRATES CARDIAC AND RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH AL AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION. HAEMATOLOGICA, 100, 2–3.
  
• 
  
• Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A. A., … Advani, A. S. (2011). Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia. BLOOD, 118(21), 1095.
  
• 
  
• 
  
• Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma Richardson, P. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., … Baz, R. (2018). Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 182(2), 231–44.
  
• Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia Yurkiewicz, I. R., Muffly, L., & Liedtke, M. (2018). Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. DRUG DESIGN DEVELOPMENT AND THERAPY, 12, 2293–2300.
  
• Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis Yen, T., Chen, F., Witteles, R., Liedtke, M., & Nguyen, L. A. (2017). Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis. AMERICAN JOURNAL OF GASTROENTEROLOGY, 112, S240.
  
• Long-term outcomes of the INO-VATE ALL study in patients with relapsed/refractory acute lymphoblastic leukemia: Response rates and survival outcomes by bone marrow blast percentage Stelljes, M., Marks, D., DeAngelo, D. J., Liedtke, M., Stock, W., Goekbuget, N., … Kantarjian, H. (2018). Long-term outcomes of the INO-VATE ALL study in patients with relapsed/refractory acute lymphoblastic leukemia: Response rates and survival outcomes by bone marrow blast percentage. ONCOLOGY RESEARCH AND TREATMENT, 41, 24–25.
  
• Antibody-based therapies in patients with acute lymphoblastic leukemia. Dinner, S., & Liedtke, M. (2018). Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology. American Society of Hematology. Education Program, 2018(1), 9–15.
  
• Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis. Gong, C. L., Studdert, A. L., & Liedtke, M. (2018). Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis. American Journal of Hematology.
  
• 
  
• A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., … Larson, R. A. (2019). A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood.
  
• 
  
• Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment Gandhi, U. H., Lakshman, A., Gahvari, Z., McGehee, E., Jagosky, M. H., Gupta, R., … Costa, L. J. (2018). Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. BLOOD, 132.
  
• Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies Varnado, W., Jagosky, M. H., Gahvari, Z., Chhabra, S., Gandhi, U. H., Lakshman, A., … Costa, L. J. (2018). Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. BLOOD, 132.
  
• 
  
• 
  
• Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Chung, A., & Liedtke, M. (2019). Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Practice & Research. Clinical Haematology, 32(1), 54–64.